340B PATIENTS Act of 2025
- Bill Number
- S. 2372
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-07-22: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-12-05T22:47:52Z
AI-Generated Summary
Purpose of the Legislation
The 340B PATIENTS Act of 2025 aims to clarify and reinforce the 340B drug discount program under Section 340B of the Public Health Service Act. This program requires drug manufacturers to provide discounted outpatient drugs to eligible healthcare providers (called "covered entities," such as hospitals and clinics serving low-income or vulnerable patients). The bill ensures these discounts apply without restrictions from manufacturers, particularly when drugs are dispensed through contract pharmacies, to help providers stretch resources and improve patient care.
Key Provisions
- Discount Obligations: Manufacturers must offer drugs at or below a set "ceiling price" (a maximum discounted rate) to covered entities, regardless of how or where the drug is dispensed, including through contract pharmacies.
- Prohibitions on Restrictions: Manufacturers cannot impose conditions that limit how covered entities buy, deliver, or use discounted drugs. Prohibited conditions include:
- Limits on delivery methods, purchase mechanisms, or dispensing locations.
- Requirements for covered entities to submit claims data or assure compliance.
- Practices that are not standard business norms, discourage program use, or disproportionately affect covered entities (unless pre-approved by the Secretary of Health and Human Services).
- Contract Pharmacies: Covered entities can partner with pharmacies to dispense discounted drugs to their patients. All program rules and manufacturer obligations apply to these arrangements, allowing providers to expand access to care.
- Enforcement and Penalties:
- The Secretary must issue regulations within 180 days to define violation standards and allow covered entities to report non-compliance (beyond just overcharges).
- Manufacturers face civil monetary penalties up to $2,000,000 per day for intentional violations, based on factors like the violation's scope, affected drugs, and impacted entities. Penalties continue until compliance is achieved.
- Findings Support: The bill highlights the program's role in saving resources (e.g., $7 billion in Medicare Part D from 2013–2017), enabling comprehensive services, and providing access to specialty drugs for serious conditions like cancer or multiple sclerosis, often only available via distant pharmacies.
Significant Changes to Existing Law
- Amendments to Section 340B(a): Adds explicit language requiring discounts "regardless of the manner or location" of dispensing and prohibiting unapproved conditions. Introduces a new paragraph (11) affirming contract pharmacy use, which was previously implied but not detailed.
- Updates to Section 340B(d): Expands penalties beyond overcharges to include other violations (e.g., imposing restrictions). Creates a formal process for covered entities to claim violations and sets standards for daily fines, enhancing enforcement tools not previously specified.
Potential Impacts
- On Citizens: Improves access to affordable medications for vulnerable patients, especially those with chronic or life-threatening conditions, by enabling safety-net providers to serve more people without resource constraints.
- On Government Agencies: The Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA, overseen by the Secretary), gains responsibilities to promulgate regulations and handle violation claims, potentially increasing administrative workload but strengthening program oversight.
- On International Relations: No direct impacts mentioned; the bill focuses on domestic healthcare pricing and access.
- Broader Effects: Could reduce drug costs for providers, indirectly lowering burdens on public programs like Medicaid and Medicare, while promoting efficient use of contract pharmacies for remote or specialized drug delivery.
Main Stakeholders Affected
- Covered Entities: Hospitals, clinics, health centers, and similar providers serving underserved communities; they benefit from unrestricted access to discounts and flexibility in dispensing.
- Drug Manufacturers: Required to comply with broader obligations and face steeper penalties; may increase compliance costs but align with existing program participation tied to Medicaid and Medicare.
- Pharmacies: Contract pharmacies gain clearer legal support for dispensing discounted drugs, expanding their role in patient care.
- Patients: Particularly those with serious illnesses relying on specialty drugs; indirect beneficiaries through enhanced provider services.
- Government: HHS/HRSA as enforcers; taxpayers via potential savings in federal health programs.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens enforceability of the 340B program by codifying clarifications on contract pharmacies and restrictions, reducing ambiguity that has led to disputes and lawsuits between manufacturers and providers. Introduces robust penalty mechanisms, potentially increasing litigation if violations occur, and empowers the Secretary's regulatory role without needing new rulemaking authority.
- Constitutional Implications: None explicitly raised; the bill operates within Congress's commerce and spending powers under the Public Health Service Act, focusing on federal program conditions without infringing on private contracts or due process.
- Political Implications: Addresses ongoing tensions in drug pricing debates by prioritizing provider and patient access over manufacturer flexibility, potentially influencing future healthcare policy on affordability and equity in the 340B program.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Merkley, Jeff [D-OR], Sen. Cantwell, Maria [D-WA]
Recent Actions
- 2025-07-22: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-07-22: Introduced in Senate
Bill Versions
- 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2025 — issued 2025-07-22 — PDF (10 pages)